{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-24-000034","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.667358+00:00","generated_at":"2026-06-04T09:11:44.007278+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Humacyte BLA for HAV gets Priority Review; PDUFA Aug 10, 2024; Q4 net loss $25.1M","bullets":["FDA accepted BLA for HAV with Priority Review in vascular trauma; PDUFA date August 10, 2024.","Raised ~$43.1M net from public offering in March 2024; additional $20M draw from Oberland.","Cash and equivalents $80.4M at Dec 31, 2023; net cash used $69.0M in 2023.","No revenue in Q4 2023; R&D expenses $20.2M (up from $15.0M), net loss $25.1M.","Full year 2023 net loss $110.8M vs $12.0M in 2022 due to non-cash remeasurement and higher expenses."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-24-000034","json":"https://secwatch.observer/filing/0001818382-24-000034.json","markdown":"https://secwatch.observer/filing/0001818382-24-000034.md","text":"https://secwatch.observer/filing/0001818382-24-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000034/0001818382-24-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000034/huma-20240322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:11:44.007278+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}